Cost-Effectiveness Of Rivaroxaban Compared With Combined Low Molecular Weight Heparin/Vitamin K Antagonist For The Treatment Of Pulmonary Embolism In China
May 1, 2018, 00:00
10.1016/j.jval.2018.04.378
https://www.valueinhealthjournal.com/article/S1098-3015(18)30678-8/fulltext
Title :
Cost-Effectiveness Of Rivaroxaban Compared With Combined Low Molecular Weight Heparin/Vitamin K Antagonist For The Treatment Of Pulmonary Embolism In China
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)30678-8&doi=10.1016/j.jval.2018.04.378
First page :
Section Title :
Open access? :
No
Section Order :
1237